Is Humana, Inc. overvalued or undervalued?

As of 5 October 2023, Humana, Inc. has moved from fair to attractive based on recent analysis. The company is currently undervalued. Key ratios include a Price-to-Earnings (P/E) ratio of 18.5, a Price-to-Book (P/B) ratio of 3.2, and a Return on Equity (ROE) of 15%. When compared to peers, UnitedHealth Group has a P/E of 22.0, while Anthem, Inc. shows a P/B of 4.0, indicating that Humana is trading at a discount relative to its competitors. Additionally, Humana's stock has outperformed the Sensex over the past year, reinforcing its attractive valuation.